Quality System Overview
This page provides a plain English reference for quality system overview under China's NMPA regulatory framework. Full content to be completed during editorial review.
Regulatory basis
- MDSAR 2021 (State Council Order No. 739)
- Medical Device Production Supervision and Administration Measures (NMPA Order No. 53)
- YY/T 0287-2017 (equivalent to ISO 13485:2016)
Key requirements
See NMPA GMP guidance for the latest inspection requirements and GMP standards applicable to your device class and manufacturing scope.
- NMPA — www.nmpa.gov.cn
- CMDE — www.cmde.org.cn
- NMPA Medical Device Registration Query — datasearch.nmpa.gov.cn
Content on this site is written with AI assistance and is intended as a navigation aid only. Always verify against official NMPA sources before making regulatory decisions. Not affiliated with NMPA or any Chinese Government body. Not legal or regulatory advice.
China NMPA Quality Management System Overview: NMPA requires manufacturers to implement and maintain a Quality Management System (QMS) in accordance with MDSAR 2021, NMPA Order No. 53, and YY/T 0287-2017 (equivalent to ISO 13485:2016). The QMS applies to all stages of the device lifecycle: design, production, storage, distribution, and post-market surveillance. Core QMS elements include: (1) Management Responsibility—leadership commitment, quality policy, and organizational structure; (2) Resource Management—personnel training, infrastructure, and supplier management; (3) Product Realization—design controls, production planning, and process controls; (4) Measurement, Analysis and Improvement—inspection, testing, complaint handling, and CAPA. The QMS must be documented in a Quality Manual with supporting procedures, work instructions, and records. NMPA verifies QMS adequacy through GMP inspections, and manufacturers must demonstrate continuous improvement through post-market surveillance and risk assessment. QMS compliance is mandatory for market authorization and post-market maintenance of approval.